ZURICH, Jan 26 (Reuters) - Actelion Ltd ATLN.VX , Europe's
biggest biotech firm, said on Tuesday that Health Canada had
granted a notice of compliance for Uptravi, a new pulmonary
arterial hypertension medicine.
The approval is "a major milestone", Chief Executive
Jean-Paul Clozel said in a statement, adding that the company is
working to make the drug available to patients in Canada "as
soon as possible".
Analysts have said Uptravi could reap more than $1 billion
in global sales annually at its peak.